We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board

News   Feb 06, 2013

 
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board
 
 
 

RELATED ARTICLES

Trial Suggests Immunotherapy Is Superior to Chemotherapy in Some Children With Relapsed Leukemia

News

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

READ MORE

A Prescription of Short-term Exercise Could Help Reduce the Side-effects of Prostate Hormone Therapy

News

A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research from the University of East Anglia.

READ MORE

Prostate Cancer "Super Responders" Live for 2 Years on Immunotherapy

News

A major clinical trial shows that some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE